Bengamide B
Bengamide B is an alkaloid with anti-tumor and anti-inflammatory activities. Bengamide B reduces the phosphorylation level of IκBα, thereby blocking the activation of NF-κB. Bengamide B inhibits the proliferation of tumor cells. Bengamide B can be used in research related to inflammatory diseases and cancers.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 104947-69-5
- Fòrmula: C32H58N2O8
- Peso molecular:598.81
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
|
IL-6 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
0.002 μM
Compound: 7
|
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay
|
[PMID: 22705020] |
| MDA-MB-435 | IC50 |
2 nM
Compound: Bengamide B
|
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 28185457] |
| RAW264.7 | IC50 |
>50 μM
Compound: 7
|
Cytotoxicity against mouse RAW264.7 cells after 18 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cells after 18 hrs by MTT assay
|
[PMID: 22705020] |
| RAW264.7 | IC50 |
0.085 μM
Compound: 7
|
Inhibition of LPS-stimulated NFkappaB activation transfected in mouse RAW264.7 cells after 18 hrs by luciferase reporter gene assay
Inhibition of LPS-stimulated NFkappaB activation transfected in mouse RAW264.7 cells after 18 hrs by luciferase reporter gene assay
|
[PMID: 22705020] |
| RAW264.7 | IC50 |
0.5 μM
Compound: 7
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated IL-6 expression up to 10 uM by quantitative RT-PCR analysis
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated IL-6 expression up to 10 uM by quantitative RT-PCR analysis
|
[PMID: 22705020] |
| RAW264.7 | IC50 |
0.5 μM
Compound: 7
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated MCP1 expression up to 10 uM by quantitative RT-PCR analysis
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated MCP1 expression up to 10 uM by quantitative RT-PCR analysis
|
[PMID: 22705020] |
| RAW264.7 | IC50 |
0.5 μM
Compound: 7
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated TNFalpha expression up to 10 uM by quantitative RT-PCR analysis
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated TNFalpha expression up to 10 uM by quantitative RT-PCR analysis
|
[PMID: 22705020] |
Bengamide B (18 h) potently inhibits NF-κB activity in RAW264.7 cells with an IC50 of 0.085 μM; it shows no cytotoxicity against RAW264.7 cells at concentrations up to 50 μM; it also potently inhibits the growth of HCT-116 cells with an IC50 of 0.002 μM[1].
Bengamide B (0-10 μM; 4 h) dose-dependently inhibits LPS (HY-D1056)-induced phosphorylation of IκBα in RAW264.7 cells[1].
Bengamide B (0.01-10 μM) dose-dependently inhibits LPS-induced expression of TNFα, IL-6 and MCP-1 in RAW264.7 cells[1].
Bengamide B (3 days) potently inhibits the proliferation of MDA-MB-435 human breast cancer cells in vitro, with an IC50 value of 0.0024 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:murine RAW264.7 macrophage cells
-
Concentration:0, 0.01, 0.1, 1, 10 μM
-
Incubation Time:4 h
-
Result:Dose-dependently reduced the level of phosphorylated IκBα, with greater inhibitory activity observed at higher concentrations.
Maintained consistent total IκBα and β-actin levels across concentrations.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Athymic (nu/nu) nude mice treated MDA-MB-435 cells[2]
-
Dosage:10 µmol/kg; 33 µmol/kg (20 mg/kg)
-
Administration:i.v.; three times per week; 3 weeks
-
Result:Produced a 45% T/C value, with a 0.5% change in average body weight and 0/8 mice dead at 10 µmol/kg.
Produced a 31% T/C value, with a -2.3% change in average body weight and 0/8 mice dead at 33 µmol/kg.
Induced statistically significant tumor growth inhibition at both doses.
Chemical Information
-
No. CAS 104947-69-5
-
Peso molecular 598.81
-
Fòrmula C32H58N2O8
-
SMILES
CC(C)/C=C/[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC)C(N[C@H]1CC[C@H](OC(CCCCCCCCCCCCC)=O)CN(C)C1=O)=O
-
Structure Classification
-
Initial Source
Jaspis digonoxea
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Johnson TA, et al. Myxobacteria versus sponge-derived alkaloids: the bengamide family identified as potent immune modulating agents by scrutiny of LC-MS/ELSD libraries. Bioorg Med Chem. 2012;20(14):4348-4355. [Content Brief]
[2]. Kinder FR Jr, et al. Synthesis and antitumor activity of ester-modified analogues of bengamide B. J Med Chem. 2001;44(22):3692-3699. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Bengamide B Related Classifications
HY-110151 Related Classifications
Powered by Bioz